Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interfant-21 international protocol for infants under 1 year with KMT2A-rearranged acute lymphoblastic leukemia
MOH_2025-06-03_012912Phase 3Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Mar 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on MOH_2025-06-03_012912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-03_012912.